Chemically Advanced Template Search (CATS) for Scaffold‐Hopping and Prospective Target Prediction for ‘Orphan’ Molecules
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
Drug discovery is driven by the identification of new chemical entities (NCEs).1,2 Virtual screening and de novo design techniques have been proven to serve this purpose, thereby complementing experimental biochemical and biological approaches.3 Still, it remains a matter of debate, which particular molecular representation and similarity index are preferable for a given drug target in order to identify appropriate NCEs with minimal synthetic and testing effort involved.4 Ligand-based chemical similarity approaches have been effectively applied to large-scale activity and target prediction for known drugs, some of the prominent methods being PASS developed by Poroikov et al.,5 the techniques conceived by Mestres and co-workers,6 and the similarity ensemble approach (SEA) implemented by the Shoichet group.7 Here, we compared several popular two-dimensional molecular representations for their ability to retrieve actives (enrichment potential) and chemotypes (scaffold-hopping potential) from a collection of druglike bioactive compounds. Subsequently the applied chemical advanced template search (CATS)8 was applied to predicting potential drug targets for a virtually assembled combinatorial compound library, from which we synthesized and successfully tested candidate compounds. The results demonstrate that CATS is not only suited for its intended purpose of NCE retrieval by scaffold-hopping,9 but also for reliable target profiling of 'orphan' virtual molecules.10 It thereby complements the suite of available validated tools for target prediction. A framework for retrospective evaluation of similarity searching runs with different molecular representations ('descriptors') was established on basis of the COBRA collection of druglike bioactive compounds,11 employing Euclidean distances for metric descriptors and the Tanimoto coefficient for fingerprint descriptors.12 COBRA contains 12 642 manually curated entries with 980 target protein subtype annotations. For 170 macromolecular drug targets with a minimum of 20 annotated active ligands per target, each compound annotated as 'active' was selected as a query in turn, and compared to all remaining compounds in the screening pool in terms of molecular descriptor similarity, finally yielding sorted results lists with the most similar or least distant pool compounds sorted to the top. Although there are large collections of bioactive compounds available in the public domain,13 we used the carefully compiled COBRA collection to i) reduce the risk of erroneous activity data and faulty compound structures,14 and ii) avoid redundancy with existing tools that are based on such public structure-activity data. In addition, we intend to probe the value of a comparably small but well curated reference compound pool for target prediction. We used a representative set of descriptors and fingerprints for benchmarking. 'Morgan' fingerprints, closely related to extended-connectivity fingerprints (ECFP), are based on radial assessment of non-predefined potentially infinite molecular fragments.17 The 'AtomPair' descriptor can be seen as a CATS predecessor merely denoting the occurrence of all pairs of atoms at a given topological distance.18 The 'MACCS' keys represent substructure-based fingerprints,19 and the 'RDkit' fingerprint implements a Daylight-like fingerprint based on hashed molecular subgraphs.20 Latter fingerprints and descriptors were calculated using the open-source software package RDkit.21 Finally, the 'MOE2D' descriptor consists of a standardized vector of physicochemical properties provided by the Molecular Operating Environment (v2011, Chemical Computing Group, Montreal). At this point, we analyzed two versions of CATS vectors, namely the originally described CATS18 and CATS2, which distinguishes lipophilic from aromatic atoms during typing, thereby resulting in more pharmacophore type pairs and consequently a higher dimensionality of the descriptor than CATS1, which lacks the aromatic atom type. For both descriptors we employed 'types scaling', which mitigates the potential dominance of prevalent pharmacophore feature types, and a maximal correlation distance of 10 bonds.22 An example of CATS descriptor calculation is presented in Figure 1. Principle of CATS descriptor calculation. The molecular structure (Step 1) is reduced to the molecular graph, and feature types are assigned (Step 2; L, lipophilic; R, aromatic; A, hydrogen-bond acceptor; D, hydrogen-bond donor). Then, atom pairs for all feature pairs are counted (Step 3), and the final descriptor values are scaled (Step 4). Here, the raw values were divided by the respective λ value (sum of atom type pair occurrences). Note that not all vertices in the molecular graph are considered 'pharmacophoric'. These possess no feature types. We employed the Receiver Operating Characteristic (ROC) related BEDROC score for actives-retrieval benchmarking.15 For our study, the alpha level of the BEDROC method was set to 160.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hierarchical Grouping to Optimize an Objective Function
Ward, J. H. (1963) · Journal of the American Statistical Association · doi:10.1080/01621459.1963.10500845 · Cited by 20,598
Individual Comparisons by Ranking Methods
Wilcoxon, F. (1945) · Biometrics Bulletin · doi:10.2307/3001968 · Cited by 15,354
Extended-Connectivity Fingerprints
Rogers, D., & Hahn, M. (2010) · Journal of Chemical Information and Modeling · doi:10.1021/ci100050t · Cited by 7,524
ChEMBL: a large-scale bioactivity database for drug discovery
Gaulton, A., Bellis, L. J., Bento, A. P., Chambers, J., Davies, M., Hersey, A., Light, Y., McGlinchey, S., Michalovich, D., Al-Lazikani, B., et al. (2012) · Nucleic Acids Research · doi:10.1093/nar/gkr777 · Cited by 4,382
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
The Properties of Known Drugs. 1. Molecular Frameworks
Bemis, G. W., & Murcko, M. A. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm9602928 · Cited by 2,482
Relating protein pharmacology by ligand chemistry
Keiser, M. J., Roth, B. L., Armbruster, B. N., Ernsberger, P., Irwin, J. J., & Shoichet, B. K. (2007) · Nature Biotechnology · doi:10.1038/nbt1284 · Cited by 2,402
Atom pairs as molecular features in structure-activity studies: definition and applications
Carhart, R. E., Smith, D. H., & Venkataraghavan, R. (1985) · Journal of Chemical Information and Computer Sciences · doi:10.1021/ci00046a002 · Cited by 1,066
The productivity crisis in pharmaceutical R&D
Pammolli, F., Magazzini, L., & Riccaboni, M. (2011) · Nature Reviews Drug Discovery · doi:10.1038/nrd3405 · Cited by 918
Large-scale prediction and testing of drug activity on side-effect targets
Lounkine, E., Keiser, M. J., Whitebread, S., Mikhailov, D., Hamon, J., Jenkins, J. L., Lavan, P., Weber, E., Doak, A. K., Côté, S., et al. (2012) · Nature · doi:10.1038/nature11159 · Cited by 881
Evaluating Virtual Screening Methods: Good and Bad Metrics for the “Early Recognition” Problem
Truchon, J.-F., & Bayly, C. I. (2007) · Journal of Chemical Information and Modeling · doi:10.1021/ci600426e · Cited by 874
Similarity-based virtual screening using 2D fingerprints
Willett, P. (2006) · Drug Discovery Today · doi:10.1016/j.drudis.2006.10.005 · Cited by 849
“Scaffold-Hopping” by Topological Pharmacophore Search: A Contribution to Virtual Screening
Schneider, G., Neidhart, W., Giller, T., & Schmid, G. (1999) · Angewandte Chemie International Edition · doi:10.1002/(sici)1521-3773(19991004)38:19<2894::aid-anie2894>3.0.co;2-f · Cited by 717
Self-citationVirtual screening: an endless staircase?
Schneider, G. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3139 · Cited by 533
Self-citationSastry, M., Lowrie, J. F., Dixon, S. L., & Sherman, W. (2010) · Journal of Chemical Information and Modeling · doi:10.1021/ci100062n · Cited by 332
Sur, C., Mallorga, P. J., Wittmann, M., Jacobson, M. A., Pascarella, D., Williams, J. B., Brandish, P. E., Pettibone, D. J., Scolnick, E. M., & Conn, P. J. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1835612100 · Cited by 294
Baviskar, A. T., Madaan, C., Preet, R., Mohapatra, P., Jain, V., Agarwal, A., Guchhait, S. K., Kundu, C. N., Banerjee, U. C., & Bharatam, P. V. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200235u · Cited by 294
Koutsoukas, A., Simms, B., Kirchmair, J., Bond, P. J., Whitmore, A. V., Zimmer, S., Young, M. P., Jenkins, J. L., Glick, M., Glen, R. C., et al. (2011) · Journal of Proteomics · doi:10.1016/j.jprot.2011.05.011 · Cited by 287
Drug repurposing: far beyond new targets for old drugs
Oprea, T. I., & Mestres, J. (2012) · The AAPS Journal · doi:10.1208/s12248-012-9390-1 · Cited by 285
The Experimental Uncertainty of Heterogeneous Public Ki Data
Kramer, C., Kalliokoski, T., Gedeck, P., & Vulpetti, A. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm300131x · Cited by 233
Stoichiometry and Physical Chemistry of Promiscuous Aggregate-Based Inhibitors
Coan, K. E. D., & Shoichet, B. K. (2008) · Journal of the American Chemical Society · doi:10.1021/ja802977h · Cited by 225
Yu, H., Ai, Y., Yu, L., Zhou, X., Liu, J., Li, J., Xu, X., Liu, S., Chen, J., Liu, F., et al. (2008) · International Journal of Cancer · doi:10.1002/ijc.23049 · Cited by 203
Kim, O., Jeong, Y., Lee, H., Hong, S.-S., & Hong, S. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm101582z · Cited by 160
Similarity Searching Using 2D Structural Fingerprints
Willett, P. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-839-3_5 · Cited by 155
Scaffold‐Hopping: How Far Can You Jump?
Schneider, G., Schneider, P., & Renner, S. (2006) · QSAR & Combinatorial Science · doi:10.1002/qsar.200610091 · Cited by 150
Self-citationOn the origins of drug polypharmacology
Jalencas, X., & Mestres, J. (2013) · MedChemComm · doi:10.1039/c2md20242e · Cited by 138
Collection of Bioactive Reference Compounds for Focused Library Design
Schneider, P., & Schneider, G. (2003) · QSAR & Combinatorial Science · doi:10.1002/qsar.200330825 · Cited by 132
Self-citationSelf-Organizing Maps in Drug Discovery: Compound Library Design, Scaffold-Hopping, Repurposing
Schneider, P., Tanrikulu, Y., & Schneider, G. (2008) · Current Medicinal Chemistry · doi:10.2174/092986709787002655 · Cited by 121
Self-citationA Ligand-Based Approach to Mining the Chemogenomic Space of Drugs
Gregori‐Puigjané, E., & Mestres, J. (2008) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/138620708785739952 · Cited by 101
Scaffold‐Hopping Potential of Ligand‐Based Similarity Concepts
Renner, S., & Schneider, G. (2005) · ChemMedChem · doi:10.1002/cmdc.200500005 · Cited by 100
Self-citationProcessing and classification of chemical data inspired by insect olfaction
Schmuker, M., & Schneider, G. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705683104 · Cited by 94
Self-citationPASS: identification of probable targets and mechanisms of toxicity
Poroikov, V., Filimonov, D., Lagunin, A., Gloriozova, T., & Zakharov, A. (2007) · SAR and QSAR in Environmental Research · doi:10.1080/10629360601054032 · Cited by 92
Informatics, I. (2011) · Claud Press eBooks · Cited by 87
BindingDB and ChEMBL: online compound databases for drug discovery
Wassermann, A. M., & Bajorath, J. (2011) · Expert Opinion on Drug Discovery · doi:10.1517/17460441.2011.579100 · Cited by 85
Voyages to the (un)known: adaptive design of bioactive compounds
Schneider, G., Hartenfeller, M., Reutlinger, M., Tanrikulu, Y., Proschak, E., & Schneider, P. (2008) · Trends in biotechnology · doi:10.1016/j.tibtech.2008.09.005 · Cited by 79
Self-citationComputational Tools for Polypharmacology and Repurposing
Achenbach, J., Tiikkainen, P., Franke, L., & Proschak, E. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.62 · Cited by 77
Effectiveness of 2D Fingerprints for Scaffold Hopping
Gardiner, E. J., Holliday, J. D., O’Dowd, C., & Willett, P. (2011) · Future Medicinal Chemistry · doi:10.4155/fmc.11.4 · Cited by 66
Predicting olfactory receptor neuron responses from odorant structure
Schmuker, M., de Bruyne, M., Hähnel, M., & Schneider, G. (2007) · Chemistry Central Journal · doi:10.1186/1752-153x-1-11 · Cited by 60
Self-citationAnticipating drug side effects by comparative pharmacology
García-Serna, R., & Mestres, J. (2010) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2010.509343 · Cited by 54
Steri, R., Achenbach, J., Steinhilber, D., Schubert‐Zsilavecz, M., & Proschak, E. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.02.027 · Cited by 41
Reutlinger, M., Guba, W., Martin, R. E., Alanine, A. I., Hoffmann, T., Klenner, A., Hiss, J. A., Schneider, P., & Schneider, G. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201105156 · Cited by 41
Self-citationDe novo design – hop(p)ing against hope
Schneider, G. (2012) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2012.06.001 · Cited by 40
Self-citationCoverage and bias in chemical library design
Gregori‐Puigjané, E., & Mestres, J. (2008) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2008.03.015 · Cited by 40
Noeske, T., Jirgensons, A., Starchenkovs, I., Renner, S., Jaunzeme, I., Trifanova, D., Hechenberger, M., Bauer, T., Kauss, V., Parsons, C. G., et al. (2007) · ChemMedChem · doi:10.1002/cmdc.200700151 · Cited by 37
Self-citationSchneider, G., Tanrikulu, Y., & Schneider, P. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.11 · Cited by 35
Self-citationHolliday, J. D., Kanoulas, E., Malim, N. H. A. H., & Willett, P. (2011) · Journal of Cheminformatics · doi:10.1186/1758-2946-3-29 · Cited by 34
Searching for Drug Scaffolds with 3D Pharmacophores and Neural Network Ensembles
Renner, S., Hechenberger, M., Noeske, T., Böcker, A., Jatzke, C., Schmuker, M., Parsons, C. G., Weil, T., & Schneider, G. (2007) · Angewandte Chemie International Edition · doi:10.1002/anie.200604125 · Cited by 27
Self-citation‘Fuzziness’ in pharmacophore-based virtual screening and de novo design
Klenner, A., Hartenfeller, M., Schneider, P., & Schneider, G. (2010) · Drug Discovery Today Technologies · doi:10.1016/j.ddtec.2010.10.004 · Cited by 26
Self-citationIn silico directed chemical probing of the adenosine receptor family
Areias, F. M., Brea, J. M., Gregori‐Puigjané, E., Zaki, M. E. A., Carvalho, M. A., Domínguez, E., Gutiérrez‐de‐Terán, H., Proença, M. F. R. P., Loza, M. I., & Mestres, J. (2010) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2010.03.048 · Cited by 26
Optimization of a Pharmacophore‐based Correlation Vector Descriptor for Similarity Searching
Fechner, U., & Schneider, G. (2004) · QSAR & Combinatorial Science · doi:10.1002/qsar.200330855 · Cited by 17
Self-citationPredicting the Performance of Fingerprint Similarity Searching
Vogt, M., & Bajorath, J. (2010) · Methods in molecular biology · doi:10.1007/978-1-60761-839-3_6 · Cited by 17
Schneider, P., Stutz, K., Kasper, L., Haller, S., Reutlinger, M., Reisen, F., Geppert, T., & Schneider, G. (2011) · Pharmaceuticals · doi:10.3390/ph4091236 · Cited by 10
Self-citationHähnke, V. D., Todoroff, N. K., Rodrigues, T., & Schneider, G. (2012) · Future Medicinal Chemistry · doi:10.4155/fmc.12.148 · Cited by 5
Self-citation
Cited by
Molecular de-novo design through deep reinforcement learning
Olivecrona, M., Blaschke, T., Engkvist, O., & Chen, H. (2017) · Journal of Cheminformatics · doi:10.1186/s13321-017-0235-x · Cited by 1,324
Counting on natural products for drug design
Rodrigues, T., Reker, D., Schneider, P., & Schneider, G. (2016) · Nature Chemistry · doi:10.1038/nchem.2479 · Cited by 1,250
Self-citationChen, Y.-C. (2015) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2014.12.001 · Cited by 611
Polypharmacology by Design: A Medicinal Chemist’s Perspective on Multitargeting Compounds
Proschak, E., Stark, H., & Merk, D. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00760 · Cited by 498
Combining generative artificial intelligence and on-chip synthesis for de novo drug design
Grisoni, F., Huisman, B. J. H., Button, A. L., Moret, M., Atz, K., Merk, D., & Schneider, G. (2021) · Science Advances · doi:10.1126/sciadv.abg3338 · Cited by 190
Self-citation
Metadata
- Authors
- Reutlinger, M., Koch, C. P., Reker, D., Todoroff, N., Schneider, P., Rodrigues, T., & Schneider, G.
- Venue
- Molecular Informatics
- Publisher
- Wiley
- Published
- 2013-02
- Volume
- 32
- Issue
- 2
- Pages
- 133-138
- ISSN
- 1868-1743 (ISSN-L)
- 1868-1751
- OpenAlex
- W2061937956
- Cited by
- 166
- References
- 53
- FWCI
- 16.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.